Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Rating of “Moderate Buy” by Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has been given an average recommendation of “Moderate Buy” by the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $15.80.

AMRX has been the subject of a number of recent analyst reports. Truist Financial upped their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. UBS Group began coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective for the company. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Wall Street Zen downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 13th. Finally, Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares in the company, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 17.30% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Spire Wealth Management raised its holdings in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Amneal Pharmaceuticals by 1.2% during the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock valued at $1,229,000 after acquiring an additional 1,159 shares in the last quarter. Hsbc Holdings PLC increased its holdings in shares of Amneal Pharmaceuticals by 1.6% during the fourth quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock valued at $1,297,000 after acquiring an additional 1,569 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Amneal Pharmaceuticals by 2.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock valued at $859,000 after acquiring an additional 1,582 shares in the last quarter. Finally, Comerica Bank increased its holdings in shares of Amneal Pharmaceuticals by 56.1% during the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock valued at $59,000 after acquiring an additional 1,685 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Up 0.2%

Shares of Amneal Pharmaceuticals stock opened at $16.28 on Thursday. The company has a market cap of $5.19 billion, a PE ratio of 42.84 and a beta of 1.30. The business has a 50 day moving average of $13.26 and a 200 day moving average of $13.18. Amneal Pharmaceuticals has a 52 week low of $7.66 and a 52 week high of $16.61.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The company had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. On average, research analysts anticipate that Amneal Pharmaceuticals will post 0.92 earnings per share for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.